Finerenone in the management of diabetes kidney disease
Authors:
Open Access
- 8 February 2025
- journal article
- review article
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Abstract
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.Keywords
This publication has 31 references indexed in Scilit:
- Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021Kidney International Reports, 2022
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialNature Medicine, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2020
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus DeathJournal of General Internal Medicine, 2010
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999